Member Info for VikR

Hi sorry lost your message in the posts

My wife is in finance so you may have confused me with someone else

On another note nice to posts from fellow investors to drown out the noise and pollution of the board.

My cousin has brought in this morning @ 30k 9.75p, he is in it for the long term so more shares taken out of the hands of day traders

stay vested astute investors

Have a read of Charles Archers well written balanced article posted earlier, very pragmatic and intelligently written IMO

Ketan Patels strategic appointment has happened at a pivotal apt time of the IMM journey. The two doctors appointed to senior positions know whats happening and they are now set for life, a tremendous career move for them respectively

'Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief Scientific Officer and Dr Laura Mauran-Ambrosino has been promoted to Head of Research and Development, of the Company.'

Https://thatstocksguy.substack.com/p/8d85b637-6716-4abd-9d72-2e3138145fc2?updated=2025-10-13T13%3A20%3A10.405Z&free_preview=false

Some Highlights below that stood out to me:

Immupharma has been on a tear since the start of September.

But it’s worth considering the background: the team attended the JP Morgan, Biotech Showcase & Bio-Europe Spring Conference healthcare conferences earlier in the year.

We’re after a commercial deal after all.

On 1 Sepetember, Dr Sébastien Goudreau was been promoted to Chief Scientific Officer and Dr Laura Mauran-Ambrosino to Head of Research and Development - at the same time as the patent RNS.

CEO Tim McCarthy noted:

‘As we continue to move forward on the next step of our corporate journey, which is the partnering and commercialisation of our product portfolio, P140 in particular, it is important that our R&D team is at the forefront of our interactions and negotiations with current and future commercial partners.’

Then on 13 October, it seemed that JP Morgan conference paid off, with Ketan Patel (formerly of JP Morgan and EdenTree Investment Management) coming on board as a NED.

Even with appropriate skepticism, this is the kind of development that makes you pay attention.

The unmet need in autoimmune disease is genuine and massive.

The limitations of current therapies are real.

And the logic of ImmuPharma’s approach of precision diagnosis plus targeted normalization rather than broad suppression, is exactly where medicine has been trying to go.

We’re in an era where precision medicine is moving from aspiration to reality, where we’re finally getting the tools to subdivide diseases into meaningful categories and match patients to therapies likely to work for them specifically.

>>For investors and pharma partners, it’s a rare combination of scientific innovation, commercial opportunity, and genuine medical need

Fellow investors

hope to see some of you at the FAB headquarters this Thursdays AGM to share our shared passion for the success of fusion antibodies latest and greatest offering - Optimal

What a pivotal part of the transformational journey that is upon us

Optimal superseding all expectations so far, the accuracy levels from the last RNS 17/09 were mind blowing - six log dynamic range of affinities, it has exceeded expectation thus far as reported by our CEO

So close so close to the finale

Hope this proves to be a good decision

Just brought

20k at 6.9p

2 lots of 5k at 6.5/6.6p

Why don't the derampers sell out now, if you feel it is too much of a high risk best to exit now. All the more shares for the real long term institutional investors. Real excited to get more of these shares in the hands of bigger fund managers. This appointment has been several months in the making and executed at the right time of the journey. Additionally the negotiations continue independently of the activities of Ketan Patel, this has been confirmed by Lisa. We also have other assets to focus on in the portfolio post deal and the business wont come to a standstill on day of deal announcement so financing activities like todays announcement are crucial to long term success and viability of IMM.

This RNS is brilliant news for the person who can dissect it and appreciate it from a commercial business perspective.

Anything below 100 million MC and big investors are not interested in such shares. At the moment we are at the behest of day traders and volatility from PIs, once we get the bigger investors on board SP will rise and stay higher with less fluctuations. Ketan Patel is a seasoned investor and his appointment is brought in WITH IMMEDIATE effect to get the big investors on board. Had a long chat with Lisa with this morning and feel completely reassured with this news. The plan is on track and Ketan is already engaged with getting strategic funders on board. He has a lot of contacts and has access to the p140 data room so knows how much of a good return there is in p140, BioCIN and BioAMB. Expect TR1s to land the coming days which will silence the critics and put substance to my words rather then anecdotal statements.

Best evidenced based clinical asset buy of 2025

They made it quite clear the raise was to accelerate the commercialization of Optimal which is set to launch in 2 months or sooner from now, if you want to state objective quantifiable information.

I have been following your antics since a year and every time you have forecast a dip it has done the opposite. It seems stt1 your negative deramping has an inversely proportional relationship to the SP. Perhaps you know more then you let on and wish to buy in and load heavy or scare PIs into selling to get a better entry. Based on your historical posts urge all intelligent investors not to fall into the trap.

Stay safe, grounded and steadfast in your holdings

As you stt1 the chartist has predicted or hypothesized a SP movement, this is not always expected to happen the following day(s). If all shares worked like this we would become millionaires every other week.

Fundamentals are as resilient as ever and with optimal around the corner there has never been and let me REPEAT THIS TO EMPHASISE THE POINT a more safer and secure time to be invested into FAB. Intelligent PI investors, institutional investors and the BoD all know this.

Been here since 7-8p days and not selling a single share until another zero gets added to the above numbers

Stay vested astute investors, the conclusion is drawing near

There is no placing coming

The business is in a solid footing and everything is being put into Optimal launch. Official opening of Optimal will be the prerequisite for lots of deals to be done. The time saved in getting to clinic from refined better quality antibodies will appeal to all pharma manufacturers and only optimal has the multitude of capabilities to do that. Furthermore the grants are running and more will probably come with the FMI collaboration and invest Northern Ireland schemes. FaB will obliterate all competition with Optimal simply because no one can get close to its capacity (at present). Optimal will dominate mammalian humanization of antibodies for at least the next few years.

Expect multiple licensing contracts and then eventually a takeover bid

Just opened a junior ISA for my little one and did a 5k top up at 037.77. Every bit helps and he can keep it locked away for the next 6 years

Ridiculously cheap atm they don’t get more credible than Sir Sam Garrett leading the helm. A very astute, knowledgeable leader with a proven track record. A natural re rate is on the way prior to the next RNS which is going to yield positive results either way.

Managed a top up at 10k for 3.1p, easy load and hold and so glad to have held all the way through the dip these last few months

Strong hold fundamentals remain intact and nothing has changed. MMs need your shares and are trying to drop the bid to spiral a selling war. This pattern almost always transpires before big news.

Load and hold if you can afford to do so, a safe bet for the near term

one 2 many

did you actually just say that

you vulgar, disgusting ****** individual. instant report and hope they revoke your membership with immediate effect.

Hearing on the telegram group of some attendees who managed to catch up with CEO Mr Kinkaid at the investor meet yesterday, he was very positive and upbeat about the next 12 months and optimal remains on target. Was also mention of continued US interest which aligns with the longer term commercial strategy.

Last top up was done 17/9 at 18.3p for £20k - will look to add more at these lower levels now to take advantage of the dip.

Remain steadfast and patient astute investors, this journey remains on track and to target.

This SP has taken the market by storm and will be topping up on the bell and holding now.

Thanks but these board members are insulting and derogatory. They nitpick every sentence, find fault whilst not focusing on the content or essence. All seem to be a bunch of sad keyboard warriors with no evidence based arguments just Tim’s past performance as theonly thing they can clinch onto to drive negative sentiment. As we all know the business has moved miles since then and in a completely different shape now for reasons disclosed historically. The noise on here does not bother me as someone mentioned that we are here to make money and when we win -WE WIN TOGETHER. No doubt I have made tons of mistakes on this post which I await the de rampers to dissect and point out.

The best evidence led clinical asset buy of 2025

P140

BioCIN

BioAMB

P140 tweaked derivatives being researched

So close at the latter part of this journeys conclusion now

Once again multiple posters deviating from the topic DELIBERATELY in an attempt to derail the SP, however I will bring it back to IMM, this board is not a forum for my background and having to defend what I own or what my profession is, totally irrelevant having to constantly justify myself to the imbecile derampers.

The best clinical asset evidenced based buy of 2025, SP is set for a an exponential rise to 80p and beyond as per recent charting analysis. Ignore the waffle, foolish remarks and everything in between, idiotic posters are now establishing a pattern.

Fellow IMMers I hope you follow my sentiment and apologies in advance for any grammatical errors don’t have time to proof read sometimes

I brought 10k shares in a company I like to add to my existing sizable holdings, what’s the issue with that ? . I contribute on a board on a share I’m actually invested in. Nonsensical making non issues out of a top up, lame as it gets as a dreamier